Trials / Completed
CompletedNCT02167711
Treatment for Bile Duct Cancer in the Liver
Selective Internal Radiation Therapy With Yttrium-90 Resin Microspheres Followed by Gemcitabine Plus Cisplatin for Intra-hepatic Cholangiocarcinoma: A Phase II Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Chinese University of Hong Kong · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The current standard treatment of inoperable intrahepatic cholangiocarcinoma (bile duct cancer in the liver) is chemotherapy, which is of limited efficacy. The use of selective internal radiotherapy treatment (SIRT-Y90) is proven efficacious in patients with intra-heptic tumor. Previous experience with SIRT is safe in patients with intrahepatic cholangiocarcinoma. This study aims to study the benefits of sequential administration of SIRT followed by standard chemotherapy for treatment of inoperable intrahepatic cholangiocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SIRT Yttrium-90 |
Timeline
- Start date
- 2014-09-17
- Primary completion
- 2023-01-31
- Completion
- 2023-02-08
- First posted
- 2014-06-19
- Last updated
- 2023-04-21
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT02167711. Inclusion in this directory is not an endorsement.